The ECE1 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human Raji B lymphocyte line, engineered to disrupt the ECE1 gene. This gene encodes endothelin-converting enzyme 1, a critical metalloprotease responsible for the proteolytic activation of big endothelin-1 to mature endothelin-1. Disruption of ECE1 abolishes this conversion, creating a loss-of-function model for investigating endothelin signaling in a lymphoid context. The polyclonal format provides a heterogeneous pool of edited cells, facilitating robust population-level studies without clonal selection artifacts.
The Raji host cell line originates from a Burkitt lymphoma and is Epstein-Barr virus (EBV)-positive, retaining features of mature B lymphocytes. These suspension cells are widely employed in immunology and oncology research for studying B cell biology, lymphomagenesis, and immune surveillance mechanisms. Their transformation status and ease of culture make them a versatile platform for gene knockout studies aimed at dissecting signaling pathways relevant to lymphocyte function and disease.
ECE1 sits at the apex of the endothelin axis, processing big endothelin-1 into endothelin-1, which signals through G protein-coupled receptors EDNRA and EDNRB. Downstream cascades include G-protein-mediated activation of phospholipase C (PLC), protein kinase C (PKC), the MAPK/ERK pathway, and PI3K/Akt signaling, ultimately regulating intracellular calcium and gene expression. ECE1 activity is modulated by upstream factors such as hypoxia, shear stress, cytokines TNF-alpha and IL-1beta, and transcription factor KLF4. Interacting partners encompass the endothelin-1 precursor, EDNRA, and caveolin-1. In this knockout model, the interruption of endothelin-1 production disrupts these interconnected networks, providing a clean experimental background to dissect endothelin-dependent and -independent effects.
In the Raji B cell context, ECE1 knockout impacts potential autocrine and paracrine endothelin signaling, which may influence lymphocyte proliferation, apoptosis, and immune effector functions. Given the emerging roles of endothelin in inflammation and cancer, this model is particularly relevant for exploring how the endothelin pathway contributes to Burkitt lymphoma pathology and B cell biology. It also enables examination of crosstalk between GPCR signaling and key lymphocyte survival pathways, offering insights into therapeutic vulnerabilities in EBV-positive lymphomas.
These polyclonal knockout cells support a variety of research applications, including functional dissection of ECE1 in B cell signaling, validation of endothelin pathway-targeted therapeutics, and investigation of tumor-promoting mechanisms in lymphoma. Typical assays include Western blotting for ECE1, endothelin-1 ELISA to confirm loss of mature peptide, RT-qPCR for downstream targets, flow cytometry for EDNRA/EDNRB expression, and functional assays such as apoptosis, proliferation, and migration. GPCR signaling assays can further characterize pathway alterations. For further details or customized solutions, please contact Ascent Research.
